Antisense technology

International Journal of Pharmaceutical Sciences Review and Research

Volumn 9, Issue 2, 2011, Pages 38-45

  Gupta, Stuti ^a   Singh, Ravindra Pal ^b   Rabadia, Nirav ^a   Patel, Gaurang ^a   Panchal, Hiten ^a  

^a JAIPUR NATIONAL UNIVERSITY   (India)

^b SURESH GYAN VIHAR UNIVERSITY   (India)

Author keywords

Antisense technology; Gene expression; Protein production

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DOUBLE STRANDED RNA; MESSENGER RNA; OLIGODEOXYRIBONUCLEOTIDE; RETROVIRUS VECTOR; VIRUS RNA;

ALTERNATIVE RNA SPLICING; ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; DNA MODIFICATION; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; ELECTROPORATION; ENDOCYTOSIS; EX VIVO GENE TRANSFER; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENE TECHNOLOGY; GENETIC CODE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYBRID GENE; IN VITRO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MICROINJECTION; MOLECULAR CLONING; NONHUMAN; PLANT GENE; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REGULATOR GENE; REVIEW; RNA PROBE; RNA SEQUENCE; RNA TRANSCRIPTION; RNA TRANSLATION; TRANSGENIC PLANT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 80052657107     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Barbara. Antisense RNA: A mechanism to inhibit gene expression. 2002. http://www.fhcrc.org/visitor/research/firsts/antisense.html
2. Bochet, A., Convreur, P., Fattal, E., Intravitreal administration of antisense oligonucleotides, 2000, (19), 131-147.
3. Scalas, s., Portela, G., Fedele, M., Adenovirus-mediated suppression of HMGI. 2000, (97), 4256-61
4. Zhou, C, Bahner, I, Rassi, J.J., Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication, 1996, 6(1),17-24, U.S.A.
5. Lisziewicz, j., Sun, D., Lisziewicz, A., Gallow, R.C., Antitat gene therapy: a candidate for late stage AIDS patients. 1995, 218-222., U.S.A.
6. Chuah, M.K., Vandendriessche, T., Chang, H.K., et. al., Inhibition of human immunodeficiency virus type of retroviral vector expressing antisense - TAR, 1994, 1467-75, U.S.A.
7. Lo, K.M., Biosala, M.A., et. al., Inhibition of Replication of HIV-1 by retroviral vectors expressing tat antisense and antitat ribozyme RNA, 1992,290 (1), 176-88, (Bostan), USA.
8. Sczalkiel, G., Oppenloner, M., et. al., Tat and Rev. directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type-1, 1992, 5576-81,(Hemberg), Germany.
9. Watson, J.D., Crick, F.H., Molecular structure of nucleic acids. A structure for deoxyribose nucleic acid. 1953. Ann N Y Acad Sci. 1995,758,13-14.
10. Feeley, B.T., Poston, R.S., Park, A.K., Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynucleotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts. Transplantation. 2000,(69),1067-1074.
11. Lu, R., Serrero, G., Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proc Natl Acad Sci., USA. 2000,97,3993-3998.
12. Koller, E., Gaarde, W.A., Monia, B.P., Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol Sci., 2000,(21),142-148.
13. Cook, J., Chen, L., Bhandaru, S., The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuroblastoma and mesangial cells. Antisense Res Dev. 1992,(2),199-210.
14. Engelhard, H.H., Antisense oligodeoxynucleotide technology: potential use for the treatment of malignant brain tumors. Cancer Control. 1998,(5),163-170.
15. Murano, M., Maemura, K., Hirata, I., Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 2000,(120),51-58.
16. Moon, I.J., Choi, K., Choi, Y.K., Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1. J Biol Chem. 2000,(275),4647-4653.
17. Pagnan, G., Stuart, D.D., Pastorino, F., Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst. 2000,(92),253-261
18. Agrawal, S., Kandimalla, E.R., Antisense therapeutics: is it as simple as complementary base recognition?. Mol Med Today. 2000,(6),72-81.
19. Mani, S., Gu, Y., Wadler, S., Antisense therapeutics in oncology: points to consider in their clinical evaluation. Antisense Nucleic Acid Drug Dev. 1999,(9),543-547.
20. Martens, J.R., Reaves, P.Y., Lu, D., Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci USA. 1998,(95),2664-2669.
21. Re, R.N., Cook, J.L., Suppression of cellular proliferation using p53 DNA recognition site-related oligonucleotides. Am J Med Sci. 1996,(311),65-72.
22. Hammond, S.M., Bernstein, E., Beach, D., An RNAdirected nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000,(404),293-296.
23. Damha, Masad., Making Sense of Antisense. 2002
24. Calkins, Katrina, et. al. Prevention. 1996.
25. Kimball, J., Antisense RNA. 2002.
26. Dantus, Marcos., Fall., Antisense Olgionucleotide Technology in AIDS Research. 1997.
27. Richard, R.E., "Application of Antisense Technology to medicine, "Alton Ochsner medical Foundation, Noworleans, L.A. (U.S.A), 2002, 143-149, 163-170.